Second trimester serum predictors of congenital heart defects in pregnancies without chromosomal or neural tube defects

Prenatal Diagnosis

Volumn 31, Issue 5, 2011, Pages 466-472

  Jelliffe Pawlowski, Laura ^a   Baer, Rebecca ^a   Moon Grady, Anita J ^b   Currier, Robert J ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alpha fetoprotein; Congenital heart defects; Human chorionic gonadotrophin; Prenatal diagnosis; Prenatal screening; Unconjugated estriol

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL;

ADULT; ARTICLE; CHROMOSOME ABERRATION; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DISEASE SEVERITY; ESTRIOL BLOOD LEVEL; FEMALE; FETUS; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; NEURAL TUBE DEFECT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY;

ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; CHROMOSOME ABERRATIONS; ESTRIOL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; NEURAL TUBE DEFECTS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 79954902399     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2720     Document Type: Article

References (30)

1. American Medical Association. 2008. International classification of diseases, 9th Revision, Clinical modification.
2. Barkehall-Thomas A, Tong S, Baker LS, Edwards A, Wallace EM. 2006. Maternal serum activin A and the prediction of intrauterine growth restriction. Aust N Z J Obstet Gynaecol 46(2): 97-101.
3. Bjorklund NK, Evans JA, Greenberg CR, Seargeant LE, Schneider CE, Chodirker BN. 2004. The C677T methylenetetrahydrofolate reductase variant and third trimester obstetrical complications in women with unexplained elevations of maternal serum alpha-fetoprotein. Reprod Biol Endocrinol 2: 65.
4. Botto LD, Correa A, Erickson JD. 2001. Racial and temporal variations in the prevalence of heart defects. Pediatrics 107(3): E32.
5. Brandalize AP, Bandinelli E, dos Santos PA, Roisenberg I, Schuler-Faccini L. 2009. Evaluation of C677T and A1298C polymorphisms of the MTHFR gene as maternal risk factors for Down syndrome and congenital heart defects. Am J Med Genet A 149A(10): 2080-2087.
6. Canfield MA, Honein MA, Yuskiv N, et al. 2006. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 76(11): 747-756.
7. Cedergren MI, Kallen BA. 2006. Obstetric outcome of 6346 pregnancies with infants affected by congenital heart defects. Eur J Obstet Gynecol Reprod Biol 125(2): 211-216.
8. Craig WY, Haddow JE, Palomaki GE, Roberson M. 2007. Major fetal abnormalities associated with positive screening tests for Smith-Lemli-Opitz syndrome (SLOS). Prenat Diagn 27(5): 409-414.
9. Desgrosellier JS, Mundell NA, McDonnell MA, Moses HL, Barnett JV. 2005. Activin receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev Biol 280(1): 201-210.
10. Devore GR. 2000. Trisomy 21: 91% detection rate using second-trimester ultrasound markers. Ultrasound Obstet Gynecol 16(2): 133-141.
11. Dugoff L, Hobbins JC, Malone FD, et al. 2005. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106(2): 260-267.
12. Friedberg MK, Silverman NH, Moon-Grady AJ, et al. 2009. Prenatal detection of congenital heart disease. J Pediatr 155(1): 26-31.
13. Ganapathy R, Lamont RF, Bassett P. 2007. Unexplained elevated maternal serum beta-HCG concentration and adverse pregnancy outcome. Prenat Diagn 27(11): 995-999.
14. Gembruch U, Shi C, Smrcek JM. 2000. Biometry of the fetal heart between 10 and 17 weeks of gestation. Fetal Diagn Ther 1(1): 20-31.
15. Honein MA, Kirby RS, Meyer RE, et al. 2008. The association between major birth defects and preterm birth. Matern Child Health J 13(2): 164-175.
16. Jelliffe-Pawlowski LL, Walton-Haynes L, Currier RJ. 2008. Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Am J Med Genet A 146A(19): 2455-2467.
17. Jelliffe-Pawlowski LL, Walton-Haynes L, Currier RJ. 2009. Identification of second trimester screen positive pregnancies at increased risk for congenital heart defects. Prenat Diagn 29(6): 570-577.
18. Khoshnood B, De Vigan C, Vodovar V, et al. 2005. Trends in prenatal diagnosis, pregnancy termination, and perinatal mortality of newborns with congenital heart disease in France, 1983-2000: a population-based evaluation. Pediatrics 115(1): 95-101.
19. Kiran TS, Bethel J, Bhal PS. 2005. Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J Obstet Gynaecol 25(3): 253-256.
20. Legge M, Duff GB, Pike L, Aickin DR. 1985. Second trimester maternal serum alpha-fetoprotein as an indicator of fetal risk. Aust N Z J Obstet Gynaecol 25(4): 266-268.
21. Mills JL, Troendle J, Conley MR, Carter T, Carter T, Druschel CM. 2010. Maternal obesity and congenital heart defects: a population-based study. Am J Clin Nutr 91(6): 1543-1549.
22. Pradat P, Francannet C, Harris JA, Robert E. 2003. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. Pediatr Cardiol 24(3): 195-221.
23. Simpson LL, Malone FD, Bianchi DW, et al. 2007. Nuchal translucency and the risk of congenital heart disease. Obstet Gynecol 109(2): 376-383.
24. Smrcek JM, Berg C, Geipel A, Fimmers R, Diedrich K, Gembruch U. 2006. Early fetal echocardiography: heart biometry and visualization of cardiac structures between 10 and 15 weeks' gestation. J Ultrasound Med 25(2): 173-182.
25. Souter VL, Nyberg DA, El Bastawissi A, Zebelman A, Luthhardt F, Luthy DA. 2002. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21. Prenat Diagn 22(3): 175-182.
26. Tegnander E, Eik-Nes SH. 2006. The examiner's ultrasound experience has a significant impact on the detection rate of congenital heart defects at the second-trimester fetal examination. Ultrasound Obstet Gynecol 28(1): 8-14.
27. van Beynum IM, Kouwenberg M, Kapusta L, et al. 2006. MTRR 66A > G polymorphism in relation to congenital heart defects. Clin Chem Lab Med 44(11): 1317-1323.
28. Verheijen PM, Lisowski LA, Stoutenbeek P, et al. 2001. Prenatal diagnosis of congenital heart disease affects preoperative acidosis in the newborn patient. J Thorac Cardiovasc Surg 121(4): 798-803.
29. Wald NJ, Morris JK, Walker K, Simpson JM. 2008. Prenatal screening for serious congenital heart defects using nuchal translucency: a meta-analysis. Prenat Diagn 28(12): 1094-1104.
30. Westin M, Saltvedt S, Bergman G, Almstrom H, Grunewald C, Valentin L. 2006. Is measurement of nuchal translucency thickness a useful screening tool for heart defects? A study of 16, 383 fetuses. Ultrasound Obstet Gynecol 27(6): 632-639.